#ftcvsbigpharma

The FTC’s lawsuit against the three largest pharmacy benefit managers (PBMs) – OptumRx, Caremark Rx, and Express Scripts – ignites a debate on who’s really to blame for America’s soaring insulin costs. These PBMs are accused of inflating drug prices to maximize profits, deeply impacting patients who rely on life-saving medications. With more than 1,200% price hikes for insulin brands like Humalog over 18 years, do we need a systemic overhaul? Can this legal battle bring meaningful change to drug pricing, or will it just shift blame without addressing the root causes? Let’s discuss!